NUDT2 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, RNA-seq gene expression and subsequent network analysis in chronic myelogenous leukemia cells in culture highlighted the potential of NUDT2 as a therapeutic target, as inhibition of NUDT2 significantly affected gene pathways involved in metastasis, invasion, and apoptosis [31].